Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dutogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 18/20 | 1.00 |
| ▸ | FAP | Q12884 | 19/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.72 |
| ▸ | PREP | P48147 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dutogliptin SCHEMBL5502671 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL1236486 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL164106 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL8030287 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL8160917 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL13713813 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL7901017 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL13997343 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL7898224 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL7896597 | 0.92 | FAP (0.85) | FAPDPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | claimed |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | disclosed |
| WO-2021104355-A1 | IMPURITIES OF HETEROCYCLIC BORONIC ACID COMPOUNDS AND CONTROL METHOD THEREOF | 杭州华东医药集团新药研究院有限公司 | 2021-06-03 | — | — | WO | disclosed |
| US-8415295-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415295-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100247642-A1 | STABLE PHARMACEUTICAL FORMULATION FOR A DPP-IV INHIBITOR | PHENOMIX CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2009094462-A1 | A CRYSTALLINE SYNTHETIC INTERMEDIATE FOR PYRROLIDIN-3-YL-GLYCYLAMINOALKYLBORONATES | PHENOMIX CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009091663-A1 | STABLE PHARMACEUTICAL FORMULATION OF A DPP-IV INHIBITOR WITH METFORMIN | PHENOMIX CORPORATION (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2008144730-A2 | STABLE PHARMACEUTICAL FORMULATION FOR A DPP-IV INHIBITOR | PHENOMIX CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008109681-A2 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | PHENOMIX CORPORATION (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20070299036-A1 | PYRROLIDINE COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | PHENOMIX CORPORATION | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, ING2 | DPP4 1/4885FAP 850/4885DPP8 8/4885 |
| US-20070299036-A1 | PYRROLIDINE COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 26/4885DPP8 4/4885 |
| US-20100247642-A1 | STABLE PHARMACEUTICAL FORMULATION FOR A DPP-IV INHIBITOR | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 411/4885DPP8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.